Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atecegatran metoxil
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atecegatran metoxil is an investigational oral anticoagulant developed as a prodrug that is converted in vivo to AR-H067637, a selective and reversible direct thrombin inhibitor. By inhibiting thrombin (factor IIa), it prevents the conversion of fibrinogen to fibrin, thereby reducing blood clot formation. It was primarily investigated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Clinical development reached phase II trials but was discontinued due to limitations related to long-term stability of the extended-release formulation[1][2][3][4][5][6].
- Other names
- atecegatran fexenetilatecegatranum metoxilum
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on atecegatran metoxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atecegatran metoxil.